GenEditBio
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
21 Strathmore Rd, Natick, Massachusetts,...Website
www.geneditbio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About GenEditBio
GenEditBio specializes in advanced gene editing technologies and solutions. Their products and services cater to researchers and organizations in the biotechnology and pharmaceutical sectors. The company aims to facilitate groundbreaking discoveries and innovations in genetic research. With a focus on precision and efficiency, GenEditBio supports clients in achieving their scientific goals.Explore more
Popular SearchesGenEditBio LtdSIC Code 87,873NAICS Code 54,541Show moreGenEditBio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is GenEditBio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if GenEditBio had a recent Job posting/layoffs
Check if GenEditBio has recently received funding, and reach out quickly before it becomes old news!
GenEditBio, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if GenEditBio is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at GenEditBio
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when GenEditBio launches new products
Earning: See what the market has to say on GenEditBio recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once GenEditBio has new funding data
Recommended Actions
Reach out to Masked Content who joined GenEditBio as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
GenEditBio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
GenEditBio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about GenEditBio.
GenEditBio Tech Stack
A closer look at the technologies used by GenEditBio
See more technologies
Most Recent Scoops
Partnership
Integration, Partnership, Digital Technology, Medical Research, Clinical Operations, Healthcare Operations, Healthcare Technology
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Event
Events
Event
GenEditBio News & Media
ToolGen and GenEditBio Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics
Integrates ToolGen's best-in-class CRISPR-Cas9 platform with GenEditBio's industry-leading lipid nanoparticle (LNP) delivery technology Pursues a "once-and-done" treatment paradigm for diseases with high unmet medical needs SEOUL, South Korea, Nov. 24, 2025 /PRNewswire/ -- ToolGen Inc. (KOSDAQ: 199800), a leading genome editing company based in Korea, announced today that it has entered into a strategic cross-license agreement with GenEditBio Limited ("GenEditBio"), a Hong Kong-headquartered cliGenEditBio and ToolGen Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics
Integrates ToolGen's best-in-class CRISPR-Cas9 platform with GenEditBio's industry-leading lipid nanoparticle (LNP) delivery technology Pursues a "once-and-done" treatment paradigm for diseases with high unmet medical needs SEOUL, South Korea and HONG KONG, Nov. 24, 2025 /PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a Hong Kong-headquartered clinical-stage biotechnology company specializing in novel deliveries, including lipid nanoparticle (LNP)-based delivery systems, announced today thatGenEditBio Announces First Patient Dosed in Investigator-Initiated Trial of GEB‑101, World's First In Vivo CRISPR-Cas Ribonucleoprotein-Based Genome Editing Investigational Therapy for TGFBI Corneal Dystrophy
HONG KONG, BEIJING and BOSTON, June 6, 2025 /PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology start-up company focusing on genome editing therapeutic solutions through the discovery of novel and precise Cas nucleases and the development of safe and...GenEditBio Secures Strategic Investment from Gobi Partners GBA to Accelerate Breakthrough Genome Editing Technologies
HONG KONG, Sept. 30, 2024 /PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a biotech company co-founded by Prof. ZHENG Zongli from the City University of Hong Kong that focuses on precision genome editing to provide affordable "precision DNA surgery" for genetic diseases with unmet needs, is pleased to have AEF Greater Bay Area Fund, managed by Gobi Partners GBA, a leading venture capital firm in Asia, invested in our company. The investment will be used to further
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding GenEditBio
Sign Up For FreeTo access detailed company insights
GenEditBio specializes in advanced gene editing technologies and solutions. Their products and services cater to researchers and organizations in the biotechnology and pharmaceutical sectors. The company aims to facilitate groundbreaking discoveries and innovations in genetic research. With a focus on precision and efficiency, GenEditBio supports c... Read More
